Qiao Xiao-Feng, Liu Shi-Chen, Xue Yu, Ji Qing-Hui
First Ward of Orthopedis Department, First Affiliated Hospital of Jiamusi University.
Department of Obstetrics and Gynecology, Second Affiliated Hospital of Jiamusi University, Jiamusi, China.
Medicine (Baltimore). 2020 May 22;99(21):e20350. doi: 10.1097/MD.0000000000020350.
Previous studies have reported that extracorporeal shock wave (EPSW) combined spinal core decompression (SCD) has been used for the treatment of patients with femoral head necrosis (FHN) effectively. However, their results are still inconsistent. Therefore, this study will systematically assess the efficacy and safety of EPSW and SCD for the treatment of patients with FHN.
This study will systematically search the following databases from inception through March 1, 2020: MEDLINE, Web of Science, Scopus, EMBASE, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, and China National Knowledge Infrastructure. All searches will be performed without language and publication date restrictions. This study will only include randomized controlled trials investigating the efficacy and safety of EPSW and SCD for the treatment of patients with FHN. Two authors will independently assess all literatures, extract data, and appraise risk of bias. Any confusion between 2 authors will be cleared up by a third author through discussion. RevMan 5.3 software will be utilized to analyze the data and to perform a meta-analysis if necessary.
This study will summarize up-to-date evidence and provide a detailed summary related to the efficacy and safety of EPSW and SCD for the treatment of patients with FHN.
This study may provide helpful evidence to determine whether or not EPSW combined SCD is effective and safety for the treatment of patients with FHN.
INPLASY202040092.
既往研究报道,体外冲击波(EPSW)联合脊柱核心减压(SCD)已被有效用于治疗股骨头坏死(FHN)患者。然而,其结果仍不一致。因此,本研究将系统评估EPSW和SCD治疗FHN患者的疗效和安全性。
本研究将系统检索从创刊至2020年3月1日的以下数据库:MEDLINE、科学网、Scopus、EMBASE、Cochrane图书馆、护理及相关健康文献累积索引和中国知网。所有检索将不受语言和出版日期限制。本研究仅纳入调查EPSW和SCD治疗FHN患者疗效和安全性的随机对照试验。两名作者将独立评估所有文献、提取数据并评估偏倚风险。两名作者之间的任何分歧将由第三名作者通过讨论解决。将使用RevMan 5.3软件分析数据,并在必要时进行荟萃分析。
本研究将总结最新证据,并提供与EPSW和SCD治疗FHN患者的疗效和安全性相关的详细总结。
本研究可能为确定EPSW联合SCD治疗FHN患者是否有效和安全提供有用证据。
INPLASY202040092。